Endocrinology
2-Methoxyestradiol has a biphasic effect on new vessel growth
Published in Cancer Weekly, January 13th, 2004
According to published research from the United States, "2-methoxyestradiol (2-ME2) was reported to elicit both stimulation and inhibition of tumor angiogenesis and growth depending on the dosage used. However, the mechanism(s) of the biphasic action of 2-ME2 has been elusive. Here we describe a regulatory role of vascular endothelial growth factor-A (VEGF-A) in the biphasic effects on estrogen receptor (ER) (+) GH3 rat pituitary tumor cells and MCF-7 human breast tumor cells depending on the dosage of 2-ME2 used."
"We observed that acute exposure to 2-ME2, irrespective of dosage, did not...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-01-13)
More Articles from Cancer Weekly
- Insulin-Like Growth Factor
IIp45 antagonizes IGFBP-2 stimulation of glioma cell invasion - Anticancer Drugs
Phase I clinical trial for encapsulated anticancer drug delayed until third quarter 2004 - Gastroenterology
Survivin halts gastric cancer tumorigenicity and angiogenesis - Gastroenterology
TNF-alpha may play an early role in the malignant transformation of liver cells - Gene Suppression
Small interfering RNAs staunch genes associated with cancer growth - Geriatrics
Managing older chemo patients involves preventing pharmacologic complications - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
